Dipeptidyl peptidase IV inhibition in animal models of diabetes

Advances in Experimental Medicine and Biology

Volumn 524, Issue , 2003, Pages 281-291

  Pospisilik, J Andrew ^a   Ehses, Jan A ^a   Doty, Timothy ^a   McIntosh, Christopher H S ^a   Demuth, Hans Ulrich ^b   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PROBIODRUG AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; GLUCOSE TOLERANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; INSULIN; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; PROTEASE INHIBITORS; RATS; RATS, INBRED BB;

ANIMALIA;

EID: 0038363771     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (22)

1. Mentlein, R.: 1999. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 85: 9-24
2. Lambeir, A.-M., Durinx, C., Proost, P., Van Damme, J., Scharpe, S., De Meester, I.: 2001. Kinetic Study of the Processing by Dipeptidyl-Peptidase IV/CD26 of Neuropeptides Involved in Insulin Secretion. FEBS Lett 507: 327-30
3. Pospisilik, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U., McIntosh, C.H., Demuth, H.-U.: 2001. Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept 96: 133-41
4. Kieffer, T.J., Habener, J.F.: 1999. The glucagon-like peptides. Endocr Rev 20: 876-913
5. Ehses, J., Casilla, V., Pospisilik, J., Doty, T., Demuth, H.-U., Pederson, R., McIntosh, C.: 2002. Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulates Cell Growth and Promotes Survival of INS-1 Cells (Abstract). Diabetes 51: A339
6. Perry, T., Haughey, N.J., Mattson, M.P., Egan, J.M., Greig, N.H.: 2002. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-8
7. Kieffer, T.J., McIntosh, C.H., Pederson, R.A.: 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-96
8. Pauly, R., Demuth, H.-U., Rosche, F., Schmidt, J., White, H., McIntosh, C., Pederson, R.: 1996. Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance. Regul Pept (abstract) 64: 148
9. Pauly, R.P., Demuth, H.U., Rosche, F., Schmidt, J., White, H.A., Lynn, F., McIntosh, C.H., Pederson, R.A.: 1999. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 48: 385-9
10. Pederson, R.A., White, H.A., Schlenzig, D., Pauly, R.P., McIntosh, C.H., Demuth, H.U.: 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253-8
11. Holst, J.J., Deacon, C.F.: 1998. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 Diabetes. Diabetes 47: 1663-70
12. Balkan, B., Kwasnik, L., Miserendino, R., Holst, J.J., Li, X.: 1999. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42: 1324-31
13. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K., Holst, J.J.: 2000. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85: 3575-81
14. Pospisilik, J., Stafford, S., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D., McIntosh, C., Pederson, R.: 2002. Long-term treatment with the DP IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and b-cell glucose responsiveness in VDF (fa/fa) Zucker Rats. Diabetes 51(4):943-50.
15. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Bavenholm, P., Efendic, S., Eriksson, J., Dickinson, S., Holmes, D.: 2002. Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes. Diabetes Care 25: 869-75
16. Sudre, B., Broqua, P., White, R., Ashworth, D., Evans, D., Haigh, R., Junien, J.-L., Aubert, M.: 2002. Chronic Inhibition of Circulating Dipeptidyl Peptidase IV by FE 999011 Delays the Occurrence of Diabetes in Male Zucker Diabetic Fatty Rats. Diabetes 51: 1461-69
17. Pospisilik, J.A., Stafford, S.G., Demuth, H.U., McIntosh, C.H., Pederson, R.A.: 2002. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 51: 2677-83
18. Gutniak, M., Orskov, C., Holst, J.J., Ahren, B., Efendic, S.: 1992. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-22
19. Dupre, J., Behme, M.T., Hramiak, I.M., McFarlane, P., Williamson, M.P., Zabel, P., McDonald, T.J.: 1995. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626-30
20. De Meester, I., Korom, S., Van Damme, J., Scharpe, S.: 1999. CD26, let it cut or cut it down. Immunol Today 20: 367-75
21. Steinbrecher, A., Reinhold, D., Quigley, L., Gado, A., Tresser, N., Izikson, L., Born, I., Faust, J., Neubert, K., Martin, R., Ansorge, S., Brocke, S.: 2001. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 166: 2041-8
22. Pospisilik, J., Martin, J., Doty, T., Ehses, J., Pamir, N., Lynn, F., Piteau, S., Demuth, H.-U., McIntosh, C., Pederson, R.: 2002. Long-Term DP IV-Inhibitor Treatment Reduces the Severity of Streptozotocin-Induced Diabetic Rats Through Improvements in Glucose Tolerance, Islet Size and Function and Promotion of b-cell Survival (Abst.). Diabetes 51: A343